AAH差异表达影响肝癌术后预后及其相关机制
|
摘要
肝细胞癌(HCC)是人类最常见的致命性肿瘤之一,在全球肿瘤死亡原因中排列第五,中国大陆肝癌发病率占全球发病率的55%。根治性切除是HCC治疗的首选治疗方法,但是预后尚不理想,首要原因是肝内复发。寻找理想的肝癌术后预后价值指标,并据此选择合理的辅助治疗对改善预后有重要意义。目前临床上对肝癌预后的判断主要依靠临床病理学,如TNM分期,但是它仅能对中晚期肝癌较好的做出预后判断,对于病理特征较相似的早期肝癌则在应用上有缺陷。近年研究表明,早期肝癌尽管有相似的临床病理特征,但根治性切除后病人的复发和生存情况却迥异,较大部分患者术后也会出现早期复发,据报道五年复发率近60%；按当前肝癌治疗方法的共识(如Barcelona Clinic Liver Cancer)接受肝切除者多为早期肝癌,并且随着高危人群防癌意识和早诊水平的提高,临床上早期肝癌接受肝切除者日益增加,故寻找对早期肝癌预后判断的分子标记甚为重要,迄今为止应用临床的肝癌术后预后分子标志,尤其是适用于早期者仍然缺乏。因此探索与肝癌转移和复发相关的分子,研究其调节肝癌细胞增殖和侵袭的机制,并按照该分子区分患者的预后,具有重要的临床意义。本课题在我们既往以基因芯片筛选出肝癌组织中AAH特异性高表达和体外能够调节肝癌细胞增殖、侵袭的基础上,研究AAH的调节机制以及其表达水平对肝癌术后预后尤其是探索其对早期肝癌预后的是否有判断作用,为使其成为肝癌治疗靶点提供理论和临床依据。
第一部分AAH(天冬氨酸β羟化酶)在肝癌中的表达和临床意义
目的在前期研究AAH在肝癌组织中特异性高表达和体外能够调节肝癌细胞增殖、侵袭的基础上,研究AAH的表达水平对肝癌术后预后的影响,尤其是对早期肝癌预后的预测。
方法cDNA芯片研究配对肝癌组织和癌旁组织中基因表达情况,并以RT-PCR和免疫组化证实cDNA芯片的结果。前瞻性观察2004.1-2004.6中连续入组的233例接受根治性切除患者癌组织中AAH的表达水平和预后的关系,特别是对BCLC早期(O/A)患者的预后。
结果cDNA芯片检测肝癌基因表达谱发现AAH在肝癌组织中的表达比癌旁组织高12.5倍,RT-PCR和免疫组化分别从mRNA和蛋白水平证实AAH在肝癌组织中呈过表达。分析发现AAH的表达水平与肿瘤患者血清AFP水平、肿瘤直径、肿瘤数目和TNM分期有关；AAH高表达患者复发率显著高于低表达患者,生存率则相反；多因素分析AAH是影响患者复发和生存的独立因素(hazard ratio HR,95%confidence interval, CI,复发：3.161,2.115-4.724, P<0.001;生存：2.712,1.734-4.241,P<0.001)。在BCLC A期患者中,AAH高表达患者复发率高于低表达患者,生存率相反,这在]3CLC A期直径≤5cm和>5cm患者中也得到类似的结果。而AAH的表达水平对BCLC B和C期患者术后预后没有统计学差异。
小结肝癌组织中AAH的表达水平与肝癌患者术后预后有关,对BCLC早期肝癌患者预后有预测作用,AAH高表达患者术后可能会出现复发和转移。
第二部分Gas6/Ax1信号通路与AAH的关系及其功能
目的研究AAH调节肝癌增殖和侵袭的部分机制。
方法检测Gas6/Ax1在肝癌组织和肝癌细胞系SMMC-7721、HepG2、Hep3B、PL、Hu7和正常肝细胞系L02中的表达情况；调节AAH在肝癌细胞系SMMC-7721中的表达,western blot检测下游分子Axl活性形式的表达变化以及活性形式的Axl表达变化时,肝癌细胞增殖和侵袭能力的改变,最后以免疫共沉淀证明AAH参与了Gas6/Ax1的相互作用。
结果Axl在癌组织和肝癌细胞系中的表达水平高于癌旁组织和正常肝细胞系,而Gas6表达则无差异。调节AAH在肝癌细胞系SMMC-7721中表达时,活性形式的Axl的表达出现同向变化。体外上调Axl表达时,肝癌细胞系SMMC-7721的增殖加快、侵袭能力提高；下调Axl表达时出现相反的变化。免疫共沉淀证明AAH参与了Gas6和Axl相互作用。
小结AAH调节肝癌增殖和侵袭可能部分通过Gas6/Ax1信号通路实现,Axl受体在肝癌中起癌基因作用。
第三部分Notch1与AAH的关系及其在早期肝癌术后预后中的作用
目的Notch家族的配体和受体都有大量的EGF样结构,本部分证明Notch1也受AAH的调节。鉴于Notch1信号通路的功能以及在肿瘤发生中作用,我们推测Notch1在肝癌中的表达变化在肿瘤发生中很早就表现出来,对早期肝癌术后预后有预测作用。
方法检测Notch1-4受体在肝癌组织和肝癌细胞系SMMC-7721、HepG2、Hep3B、PLC、Hu7中的表达情况；调节AAH在肝癌细胞系Hu7中的表达,westernblot检测Notch1的表达变化。前瞻性选取2004.1-2004.7年246例根治性切除的肝癌患者为研究对象,以RT-PCR,实时定量RT-PCR、western blot和免疫组化检测Notch1在肝癌组织和癌旁组织中的表达情况,分析其表达水平对直径=5cm和BCLC 0/A期患者的预后的预测作用,并以回顾性研究本院1996-2001年随机选取的227例患者的Notch1的表达水平与预后的关系验证前瞻性研究的结果。
结果除Notch1在肝癌细胞系Hu7中表达外，Notch1、2在肝癌组织和肝癌细胞系中都不表达,Notch3和Notch4在肝癌中表达不规则。调节AAH在肝癌细胞系Hu7中表达时,Notch1的表达出现同向变化。Notch1在肝癌组织中的表达低于配对癌旁组织。在前瞻性队列直径=5cm组中,Notch1低表达患者肿瘤复发时间比高表达患者短,患者生存时间相反。多因素分析发现Notch1的表达水平是影响肝癌复发和生存的独立因素。回顾性队列中的结果也证实了这一点。两个队列中还发现Notch1的表达水平对BCLC 0/A期患者的预后也是一个独立影响因素。
小结Notchl也受AAH调节,在肝癌中可能发挥抑癌基因作用,其表达水平与早期肝癌患者根治性切除术后预后密切相关。
全文结论：AAH在肝癌组织中高表达,能够调节肝癌细胞的增殖和侵袭,并与肝癌患者根治性切除术后预后相关。AAH能够调节癌基因Axl受体的表达,其作用部分机制可能通过Gas6/Ax1信号通路。Notch1也受AAH调节,由于其在肝癌中可能发挥抑癌基因作用,故AAH不通过Notch1通路调节肝癌的增殖和侵袭,但是其表达水平与早期肝癌患者根治性切除术后预后密切相关。
Hepatocellular carcinoma (HCC) is one of the most prevalent cancers and the 5th leading cause of cancer-related deaths worldwide. Although radical hepatectomy is considered as one of the first line treatment for patients with early HCC, the surgical outcome is far from satisfactory due to the likelihood of intrahepatic and extrahepatic recurrence. In clinical practice, it is still difficult to predict the prognosis for patients with early HCC due to the similarity in clinicopathologic characteristics. In fact, early-stage HCC also tends to recur and the 5-year recurrence rate was up to 60%. Patients with early-stage HCC are recommended to receive hepatectomy. Meanwhile, the number of the early stage HCC patients who undergo hepatic resection has been gradually increasing as a result of progresses in the surveillance and early detection. Although great efforts have been made for investigating precise prognostic biomarker for early HCC, the optimal candidates with clinical applicability are still lacking and urgently required. Therefore, it is clinically meaningful that metastasis and prognosis related molecule and its functional mechanism were found. In this study, the relationship between expression of AAH and the prognosis of HCC patients undergoing curative resection was evaluated based on the former study that AAH was overexpressed in HCC tissues and could regulate the invasiveness and proliferation of HCC cells in vitro.
Part 1 Expression and clinical meaning of AAH in hepatocellular carcinoma
Purpose:The association between the overexpression of aspartyl-(asparaginyl)-β-hydroxylase (AAH) and the invasiveness of hepatocellular carcinoma (HCC) in vitro has been previously studied and reported. However, the prognostic value of AAH expression in HCC remains unclear. This study was to investigate the relationship between AAH expression and tumor recurrence and patients'survival.
Methods:Overexpression of AAH was found by cDNA, and determined by RT-PCR, immunohistochemistry (IHC). The expression of AAH and prognosis of HCC patients undergoing hepatectomy, especially at BCLC 0/A stage patients, was evaluated in 233 consecutive patients recruited between January 2004 and June 2004 prospectively.
Results:We identified AAH as the most overexpressed gene in HCC by cDNA microarray hybridization. A prospective observational study of 233 patients undergoing curative resections indicated that AAH expression was an independent factor affecting the recurrence (HR,3.161,95% CI,2.115-4.724, P<0.001) and survival (HR,2.712,95% CI,1.734-4.241, P< 0.001) by multivariate analysis. Patients with AAH overexpression had a poorer prognosis in contrast with those with AAH underexpression (P<0.001 for both recurrence and survival). In BCLC stage A patients with AAH over-or underexpression, the tumor recurrence and survival rates were also statistically different (45% and 85% vs.16% and 33% in 1-and 3-year cumulative recurrence rates; 73% and 37% vs.90% and 80% in 1-and 3-year survival rates? P<0.001 for both). Furthermore, in stage A patients with tumor=5cm in diameter, the time to recurrence (TTR) was 26.7±1.6 versus 51.9±2.8 months, and the one-and three-year survival rates were 97% and 52% versus 100% and 90% in AAH over-and underexpression patients (P<0.001 for both).
Conclusion:Consequently, AAH overexpression in HCC was strongly correlated with worse surgical outcomes and this molecule likely provides a more precise prognostic predictor in early stage HCCs.
Part 2 The relationship between Gas6/Ax1 pathway and AAH, and the biological function of Gas6/Ax1.
Purpose:To investigate the mechanism of AAH regulating HCC proliferation and metastasis
Methods:The expression of Gas6 and Ax1 in HCC tissues and cell lines SMMC-7721, HepG2, Hep3B, PLC, Hu7 and HCC adjacent nontumorous tissues, normal cell line L02 were evaluated. The active form of Axl expression was examined by western blot analysis when AAH was up-or down-regulated in SMMC-7721 cell line. In addition, the proliferation and invasiveness of the cell were also evaluated correspondingly. Finally, whether AAH participated in the interaction of Gas6 and Ax1 was confirmed by immunoprecipitation.
Results:The expression of Ax1 in HCC tissues and cell lines were higher than that in nontumorous tissues and L02, but no difference was observed in Gas6 expression. And the active form of Axl expression was positively correlated with the expression of AAH. When Axl was up or down regulated, the proliferation and invasiveness of SMMC-7721 altered correspondingly. In addition, that AAH participated in the interaction of Gas6 and Ax1 was confirmed by immunoprecipitation.
Conclusion:The mechanism of AAH regulating HCC proliferation and metastasis might be through the Gas6/Ax1 pathway, and Axl played an oncogene role in HCC
Part 3 The relationship between Notchl and AAH, and the prognostic value of Notchl in early stage HCC
Purpose:Multiple EFG-like domains were found in the ligands and receptors of Notch family. In this part, that whether Notchl could be regulated by AAH would be demonstrated. Considering the function of Notchl signaling pathway and its role in tumorigenesis, we inferred that abnormal expression of Notchl could be detected in the early process of HCC formation, and could predict the surgical outcomes of early stage HCC patients.
Methods:The expression of Notchl-4 in HCC tissues and cell lines SMMC-7721, HepG2, Hep3B, PLC, and Hu7 was evaluated. The expression of Notchl was examined by western blot when AAH was up-of down-regulated in Hu7 cell line. The differential expression of Notchl was also examined by RT-PCR, western blot and immunohistochemistry. The correlation between expression level of Notchl and outcome after curative hepatectomy was investigated in training cohort of 246 patients with hepatocellular carcinoma recruited prospectively, and verified by the results of validation cohorts with 227 patients retrospectively. Patients with tumor =5cm in diameter from two cohorts which were recognized as training set (n=83), validation set (n=108), respectively, and patients at BCLC early (0/A) stage were further investigated.
Results:Neither Notchl nor Notch2 could be found in HCC tissues nor cell lines, except that Notchl could only be found in Hu7 cell line. The expression of Notch3 and Notch4 were irregular. Expression of Notchl was positively correlated with the expression of AAH by western bot analysis. Compared with paired nontumorous tissue, tumor tissue had decreased expression of Notchl. In training set, patients with high Notchl expression had better prognosis than those with low expression (49.5±2.4 vs 21.0±5.5 months, P<.001 for time to recurrence; 1-,3-year,100%,87%vs 86%, 43%, P<.001 for survival). Multivariate analysis indicated that Notchl expression level was an independent prognostic factor for both recurrence and survival (hazard ratio,95% confidence interval,4.310,2.108-8.813; 6.093,2.494-14.881, respectively). The results were fully confirmed in the analyses of validation set. Expression level of Notch1 was also an independent prognostic factor,for BCLC 0/A stage patients from two cohorts.
Conclusion:Although expression of Notchl correlated positively with that of AAH, the mechanism of AAH was not through Notchl pathway. The expression level of Notchl in tumor tissue was closely associated with time to recurrence and survival of patients with early-stage hepatocellular carcinoma undergoing hepatectomy.
In conclusion, overexpression of AAH was found in HCC tissues and cell lines, and was associated with proliferation and metastasis of HCC. Overexpression of AAH in hepatocellular carcinoma is associated with worse surgical outcomes. Axl was regulated by AAH, and the mechanism of AAH might be through Gas6/Axl pathway. Although Notchl could be regulated by AAH, the function of AAH was not through the Notch pathway. Notchl might play a tumor suppressor role in HCC and its expression level was linked to time to recurrence and survival of patients with early stage HCC.
第一部分AAH(天冬氨酸β羟化酶)在肝癌中的表达和临床意义
目的在前期研究AAH在肝癌组织中特异性高表达和体外能够调节肝癌细胞增殖、侵袭的基础上,研究AAH的表达水平对肝癌术后预后的影响,尤其是对早期肝癌预后的预测。
方法cDNA芯片研究配对肝癌组织和癌旁组织中基因表达情况,并以RT-PCR和免疫组化证实cDNA芯片的结果。前瞻性观察2004.1-2004.6中连续入组的233例接受根治性切除患者癌组织中AAH的表达水平和预后的关系,特别是对BCLC早期(O/A)患者的预后。
结果cDNA芯片检测肝癌基因表达谱发现AAH在肝癌组织中的表达比癌旁组织高12.5倍,RT-PCR和免疫组化分别从mRNA和蛋白水平证实AAH在肝癌组织中呈过表达。分析发现AAH的表达水平与肿瘤患者血清AFP水平、肿瘤直径、肿瘤数目和TNM分期有关；AAH高表达患者复发率显著高于低表达患者,生存率则相反；多因素分析AAH是影响患者复发和生存的独立因素(hazard ratio HR,95%confidence interval, CI,复发：3.161,2.115-4.724, P<0.001;生存：2.712,1.734-4.241,P<0.001)。在BCLC A期患者中,AAH高表达患者复发率高于低表达患者,生存率相反,这在]3CLC A期直径≤5cm和>5cm患者中也得到类似的结果。而AAH的表达水平对BCLC B和C期患者术后预后没有统计学差异。
小结肝癌组织中AAH的表达水平与肝癌患者术后预后有关,对BCLC早期肝癌患者预后有预测作用,AAH高表达患者术后可能会出现复发和转移。
第二部分Gas6/Ax1信号通路与AAH的关系及其功能
目的研究AAH调节肝癌增殖和侵袭的部分机制。
方法检测Gas6/Ax1在肝癌组织和肝癌细胞系SMMC-7721、HepG2、Hep3B、PL、Hu7和正常肝细胞系L02中的表达情况；调节AAH在肝癌细胞系SMMC-7721中的表达,western blot检测下游分子Axl活性形式的表达变化以及活性形式的Axl表达变化时,肝癌细胞增殖和侵袭能力的改变,最后以免疫共沉淀证明AAH参与了Gas6/Ax1的相互作用。
结果Axl在癌组织和肝癌细胞系中的表达水平高于癌旁组织和正常肝细胞系,而Gas6表达则无差异。调节AAH在肝癌细胞系SMMC-7721中表达时,活性形式的Axl的表达出现同向变化。体外上调Axl表达时,肝癌细胞系SMMC-7721的增殖加快、侵袭能力提高；下调Axl表达时出现相反的变化。免疫共沉淀证明AAH参与了Gas6和Axl相互作用。
小结AAH调节肝癌增殖和侵袭可能部分通过Gas6/Ax1信号通路实现,Axl受体在肝癌中起癌基因作用。
第三部分Notch1与AAH的关系及其在早期肝癌术后预后中的作用
目的Notch家族的配体和受体都有大量的EGF样结构,本部分证明Notch1也受AAH的调节。鉴于Notch1信号通路的功能以及在肿瘤发生中作用,我们推测Notch1在肝癌中的表达变化在肿瘤发生中很早就表现出来,对早期肝癌术后预后有预测作用。
方法检测Notch1-4受体在肝癌组织和肝癌细胞系SMMC-7721、HepG2、Hep3B、PLC、Hu7中的表达情况；调节AAH在肝癌细胞系Hu7中的表达,westernblot检测Notch1的表达变化。前瞻性选取2004.1-2004.7年246例根治性切除的肝癌患者为研究对象,以RT-PCR,实时定量RT-PCR、western blot和免疫组化检测Notch1在肝癌组织和癌旁组织中的表达情况,分析其表达水平对直径=5cm和BCLC 0/A期患者的预后的预测作用,并以回顾性研究本院1996-2001年随机选取的227例患者的Notch1的表达水平与预后的关系验证前瞻性研究的结果。
结果除Notch1在肝癌细胞系Hu7中表达外，Notch1、2在肝癌组织和肝癌细胞系中都不表达,Notch3和Notch4在肝癌中表达不规则。调节AAH在肝癌细胞系Hu7中表达时,Notch1的表达出现同向变化。Notch1在肝癌组织中的表达低于配对癌旁组织。在前瞻性队列直径=5cm组中,Notch1低表达患者肿瘤复发时间比高表达患者短,患者生存时间相反。多因素分析发现Notch1的表达水平是影响肝癌复发和生存的独立因素。回顾性队列中的结果也证实了这一点。两个队列中还发现Notch1的表达水平对BCLC 0/A期患者的预后也是一个独立影响因素。
小结Notchl也受AAH调节,在肝癌中可能发挥抑癌基因作用,其表达水平与早期肝癌患者根治性切除术后预后密切相关。
全文结论：AAH在肝癌组织中高表达,能够调节肝癌细胞的增殖和侵袭,并与肝癌患者根治性切除术后预后相关。AAH能够调节癌基因Axl受体的表达,其作用部分机制可能通过Gas6/Ax1信号通路。Notch1也受AAH调节,由于其在肝癌中可能发挥抑癌基因作用,故AAH不通过Notch1通路调节肝癌的增殖和侵袭,但是其表达水平与早期肝癌患者根治性切除术后预后密切相关。
Hepatocellular carcinoma (HCC) is one of the most prevalent cancers and the 5th leading cause of cancer-related deaths worldwide. Although radical hepatectomy is considered as one of the first line treatment for patients with early HCC, the surgical outcome is far from satisfactory due to the likelihood of intrahepatic and extrahepatic recurrence. In clinical practice, it is still difficult to predict the prognosis for patients with early HCC due to the similarity in clinicopathologic characteristics. In fact, early-stage HCC also tends to recur and the 5-year recurrence rate was up to 60%. Patients with early-stage HCC are recommended to receive hepatectomy. Meanwhile, the number of the early stage HCC patients who undergo hepatic resection has been gradually increasing as a result of progresses in the surveillance and early detection. Although great efforts have been made for investigating precise prognostic biomarker for early HCC, the optimal candidates with clinical applicability are still lacking and urgently required. Therefore, it is clinically meaningful that metastasis and prognosis related molecule and its functional mechanism were found. In this study, the relationship between expression of AAH and the prognosis of HCC patients undergoing curative resection was evaluated based on the former study that AAH was overexpressed in HCC tissues and could regulate the invasiveness and proliferation of HCC cells in vitro.
Part 1 Expression and clinical meaning of AAH in hepatocellular carcinoma
Purpose:The association between the overexpression of aspartyl-(asparaginyl)-β-hydroxylase (AAH) and the invasiveness of hepatocellular carcinoma (HCC) in vitro has been previously studied and reported. However, the prognostic value of AAH expression in HCC remains unclear. This study was to investigate the relationship between AAH expression and tumor recurrence and patients'survival.
Methods:Overexpression of AAH was found by cDNA, and determined by RT-PCR, immunohistochemistry (IHC). The expression of AAH and prognosis of HCC patients undergoing hepatectomy, especially at BCLC 0/A stage patients, was evaluated in 233 consecutive patients recruited between January 2004 and June 2004 prospectively.
Results:We identified AAH as the most overexpressed gene in HCC by cDNA microarray hybridization. A prospective observational study of 233 patients undergoing curative resections indicated that AAH expression was an independent factor affecting the recurrence (HR,3.161,95% CI,2.115-4.724, P<0.001) and survival (HR,2.712,95% CI,1.734-4.241, P< 0.001) by multivariate analysis. Patients with AAH overexpression had a poorer prognosis in contrast with those with AAH underexpression (P<0.001 for both recurrence and survival). In BCLC stage A patients with AAH over-or underexpression, the tumor recurrence and survival rates were also statistically different (45% and 85% vs.16% and 33% in 1-and 3-year cumulative recurrence rates; 73% and 37% vs.90% and 80% in 1-and 3-year survival rates? P<0.001 for both). Furthermore, in stage A patients with tumor=5cm in diameter, the time to recurrence (TTR) was 26.7±1.6 versus 51.9±2.8 months, and the one-and three-year survival rates were 97% and 52% versus 100% and 90% in AAH over-and underexpression patients (P<0.001 for both).
Conclusion:Consequently, AAH overexpression in HCC was strongly correlated with worse surgical outcomes and this molecule likely provides a more precise prognostic predictor in early stage HCCs.
Part 2 The relationship between Gas6/Ax1 pathway and AAH, and the biological function of Gas6/Ax1.
Purpose:To investigate the mechanism of AAH regulating HCC proliferation and metastasis
Methods:The expression of Gas6 and Ax1 in HCC tissues and cell lines SMMC-7721, HepG2, Hep3B, PLC, Hu7 and HCC adjacent nontumorous tissues, normal cell line L02 were evaluated. The active form of Axl expression was examined by western blot analysis when AAH was up-or down-regulated in SMMC-7721 cell line. In addition, the proliferation and invasiveness of the cell were also evaluated correspondingly. Finally, whether AAH participated in the interaction of Gas6 and Ax1 was confirmed by immunoprecipitation.
Results:The expression of Ax1 in HCC tissues and cell lines were higher than that in nontumorous tissues and L02, but no difference was observed in Gas6 expression. And the active form of Axl expression was positively correlated with the expression of AAH. When Axl was up or down regulated, the proliferation and invasiveness of SMMC-7721 altered correspondingly. In addition, that AAH participated in the interaction of Gas6 and Ax1 was confirmed by immunoprecipitation.
Conclusion:The mechanism of AAH regulating HCC proliferation and metastasis might be through the Gas6/Ax1 pathway, and Axl played an oncogene role in HCC
Part 3 The relationship between Notchl and AAH, and the prognostic value of Notchl in early stage HCC
Purpose:Multiple EFG-like domains were found in the ligands and receptors of Notch family. In this part, that whether Notchl could be regulated by AAH would be demonstrated. Considering the function of Notchl signaling pathway and its role in tumorigenesis, we inferred that abnormal expression of Notchl could be detected in the early process of HCC formation, and could predict the surgical outcomes of early stage HCC patients.
Methods:The expression of Notchl-4 in HCC tissues and cell lines SMMC-7721, HepG2, Hep3B, PLC, and Hu7 was evaluated. The expression of Notchl was examined by western blot when AAH was up-of down-regulated in Hu7 cell line. The differential expression of Notchl was also examined by RT-PCR, western blot and immunohistochemistry. The correlation between expression level of Notchl and outcome after curative hepatectomy was investigated in training cohort of 246 patients with hepatocellular carcinoma recruited prospectively, and verified by the results of validation cohorts with 227 patients retrospectively. Patients with tumor =5cm in diameter from two cohorts which were recognized as training set (n=83), validation set (n=108), respectively, and patients at BCLC early (0/A) stage were further investigated.
Results:Neither Notchl nor Notch2 could be found in HCC tissues nor cell lines, except that Notchl could only be found in Hu7 cell line. The expression of Notch3 and Notch4 were irregular. Expression of Notchl was positively correlated with the expression of AAH by western bot analysis. Compared with paired nontumorous tissue, tumor tissue had decreased expression of Notchl. In training set, patients with high Notchl expression had better prognosis than those with low expression (49.5±2.4 vs 21.0±5.5 months, P<.001 for time to recurrence; 1-,3-year,100%,87%vs 86%, 43%, P<.001 for survival). Multivariate analysis indicated that Notchl expression level was an independent prognostic factor for both recurrence and survival (hazard ratio,95% confidence interval,4.310,2.108-8.813; 6.093,2.494-14.881, respectively). The results were fully confirmed in the analyses of validation set. Expression level of Notch1 was also an independent prognostic factor,for BCLC 0/A stage patients from two cohorts.
Conclusion:Although expression of Notchl correlated positively with that of AAH, the mechanism of AAH was not through Notchl pathway. The expression level of Notchl in tumor tissue was closely associated with time to recurrence and survival of patients with early-stage hepatocellular carcinoma undergoing hepatectomy.
In conclusion, overexpression of AAH was found in HCC tissues and cell lines, and was associated with proliferation and metastasis of HCC. Overexpression of AAH in hepatocellular carcinoma is associated with worse surgical outcomes. Axl was regulated by AAH, and the mechanism of AAH might be through Gas6/Axl pathway. Although Notchl could be regulated by AAH, the function of AAH was not through the Notch pathway. Notchl might play a tumor suppressor role in HCC and its expression level was linked to time to recurrence and survival of patients with early stage HCC.
引文
[1]El-Serag HB, Rudolph KL. Hepatocellular carcinoma:epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132:2557-2576.
[2]Tang ZY. Hepatocellular carcinoma-Cause, treatment and metastasis. World J Gastroenterol 2001; 7:445-454.
[3]Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio GA, et al. Early and late recurrence after liver resection for hepatocellular carcinoma:prognostic and therapeutic implications. Ann Surg 2006; 243:229-235.
[4]Bruix J, Boix L, Sala M, Llovet JM. Focus on hepatocellular carcinoma. Cancer Cell 2004; 5:215-219.
[5]Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Intrahepatic recurrence after curative resection of hepatocellular carcinoma:long-term results of treatment and prognostic factors. Ann Surg 1999; 229:216-222.
[6]Sobin LH,Wittekind C.TNM classification of malignant tumors,6th edition. New York:UICC, Wiley-Liss,2002:81-83.
[7]Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R,Andrew K,et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001; 35:421-430.
[8]Bruix J,Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42:1208-1236.
[9]Grieco A, Pompili M, Caminiti G, Miele L, Covino M, Alfei B, et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy:comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut 2005; 54:411-418.
[10]Minagawa M, Ikai I, Matsuyama Y, Yamaoka Y, Makuuchi M. Staging of hepatocellular carcinoma:assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg 2007; 245:909-922.
[11]Yoon SK. Recent advances in tumor markers of human hepatocellular carcinoma. Intervirology.2008; 51(suppl 1):34-41.
[12]Downing, A. K., Knott, V., Werner, et al. Solution structure of a pair of calcium-binding epidermal growth factor-like domains:implications for the Marfan syndrome and other genetic disorders. Cell,1996;85:597-605.
[13]Lawrence N, Klein T, Brennan K. Structural requirements for notch signalling with delta and serrate during the development and patterning of the wing disc of Drosophila. Development 2000 Jul;127(14):3185-95.
[14]Ince N, de la Monte SM, Wands JR. Overexpression of human aspartyl (asparaginyl) beta-hydroxylase is associated with malignant transformation. Cancer Res 2000;60:1261-1266.
[15]Schena Mt Shalon D, Dais R W, et al. Quantitative monitoring of gene expression patterns with a complementary DNA microarrays. Science,1995;270(20):467-470.
[16]Gronke, R.S., D.J. Welsch, W.J. Van Dusen, et al. Partial purification and characterization of bovine liver aspartyl-β-hydroxylase. J.Biol.Chem.1990; 265:8558-8565.
[17]Frank Korioth, Christian Gieffers and Jiirgen Frey. Cloning and characterization of the human gene encoding aspartyl-β-hydroxylase. Gene 1994;150:395-399.
[18]Susan Treves, Giordana Feriotto, Luca Moccagatta. Molecular cloning, expression, functional characterization, chromosomal localization, and gene structure of junctate, a novel integral calcium binding protein of sarco(endo) plasmic reticulum membrane. J. Biol.Chem 2000;275(50):39555-39568.
[19]Jia, S, W.J. Van Dusen, R.E. Diehl, et al. cDNA cloning and expression of bovine aspartyl(asparaginyl)-β-hydroxylase. J. Biol. Chem.1992;267:14322-14327.
[20]Jia, S., K. McGinnis, W.J. VanDusen, et al. A fully active catalytic domain of bovine aspartyl(asparaginyl)-β-hydroxylase expressed in Escherichia coli:characterization and evidence for the identification of an active-site region in vertebrate a-ketoglutarate-dependent dioxygenases. Proc. Natl. Acad. Sci.1994;91:7227-7231.
[21]Gronke, R.S., W.J. VanDusen, V.M. Garsky, et al. Aspartyl b-hydroxylase:in vitro hydroxylation of a synthetic peptide based on the structure of the first growth factor-like domain of human factor IX. Proc. Natl. Acad. Sci.1989;86:3609-3613.
[22]Sunnerhagen MS, Persson E, Dahlqvist I, et al. The effect of aspartate hydroxylation on calcium binding to epidermal growth factor-like modules in coagulation factors IX and X. J. Biol. Chem.1993 Nov 5;268(31):23339-44.
[23]Stenflo, J., A. Lundwall, B. Dahlbach.β-Hydroxyasparagine in domains homologous to the epidermal growth factor precursor in vitamin K-dependent protein S. Proc. Natl. Acad. Sci. USA. 1987.84:368-372.
[24]Jhappan C, D.Gallahan C, Stahle, et al. Expression of an activated Notch-related int-3 transgene interferes with cell differentiation and induces neoplastic transformation in mammary and salivary glands. Genes Dev.1992.6:345-355.
[25]Stitt T.N., G. Conn, M. Gore, et al. The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro3/Axl family of receptor tyrosine kinases. Cell,1995,80:661-670.
[26]Joseph E. Dinchuk, Richard J. Focht, Jennifer A. Kelley. Absence of post-translational aspartyl-hydroxylation of epidermal growth factor domains in mice leads to developmental defects and an increased incidence of intestinal neoplasia. J. Biol.Chem.2002; 277(15):12970-12977.
[27]Cantarini MC, de la Monte SM, Pang M, Tong M, D'Errico A, Trevisani F, et al. Aspartyl-asparagyl beta hydroxylase overexpression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms. Hepatology 2006; 44:446-457.
[28]Luu M, Sabo E, de la Monte SM, Greaves W, Wang J, Tavares R, et al. Prognostic value of aspartyl (asparaginyl)-beta-hydroxylase/humbug expression in non-small cell lung carcinoma. Hum Pathol 2009; 40:639-644.
[29]Maeda T, Taguchi K, Aishima S, et al. Clinicopathological correlates of aspartyl (asparaginyl) beta-hydroxylase over-expression in cholangiocarcinoma. Cancer Detect Prev 2004;28:313-318.
[30]Lavaissiere.L, Jia S, Nishiyama M, et al. Overexpression of human aspartyl (asparaginyl) beta-hydroxylasein hepatocellular carcinoma and cholangiocarcinoma. J Clin Invest 1996;98:1313-1323.
[1]Bruix J,Sherman M.Management of hepatocellular carcinoma. Hepatology 2005; 42:1208-1236.
[2]Sobin LH,Wittekind C.TNM classification of malignant tumors,6th edition. New York:UICC, Wiley-Liss,2002:81-83.
[3]Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R,Andrew K,et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001; 35:421-430.
[4]Edmondson HA, Steiner PE. Primary carcinoma of the liver:A study of 100 cases among 48,900 necropsies. Cancer 1954:7; 462-503.
[5]Llovet JM, di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX et al. Design and endpoints of clinical Trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100:698-711.
[6]Downing, A. K., Knott, V., Werner, et al. Solution structure of a pair of calcium-binding epidermal growth factor-like domains:implications for the Marfan syndrome and other genetic disorders. Cell,1996;85:597-605.
[7]Lawrence N, Klein T, Brennan K. Structural requirements for notch signalling with delta and serrate during the development and patterning of the wing disc of Drosophila. Development 2000 Jul;127(14):3185-95.
[8]Ince N, de la Monte SM, Wands JR. Overexpression of human aspartyl (asparaginyl) beta-hydroxylase is associated with malignant transformation. Cancer Res 2000;60:1261-1266.
[9]Schena Mt Shalon D, Dais R W, et al. Quantitative monitoring of gene expression patterns with a complementary DNA microarrays. Science,1995;270(20):467-470.
[10]Gronke, R.S., D.J. Welsch, W.J. Van Dusen, et al. Partial purification and characterization of bovine liver aspartyl-B-hydroxylase. J.Biol.Chem.1990; 265:8558-8565.
[11]Frank Korioth, Christian Gieffers and Jiirgen Frey. Cloning and characterization of the human gene encoding aspartyl-β-hydroxylase. Gene 1994;150:395-399.
[12]Susan Treves, Giordana Feriotto, Luca Moccagatta. Molecular cloning, expression, functional characterization, chromosomal localization, and gene structure of junctate, a novel integral calcium binding protein of sarco(endo) plasmic reticulum membrane. J. Biol.Chem 2000;275(50):39555-39568.
[13]Jia, S, W.J. Van Dusen, R.E. Diehl, et al. cDNA cloning and expression of bovine aspartyl(asparaginyl)-β-hydroxylase. J. Biol. Chem.1992;267:14322-14327.
[14]Jia, S., K. McGinnis, W.J. VanDusen, et al. A fully active catalytic domain of bovine aspartyl(asparaginyl)-β-hydroxylase expressed in Escherichia coli:characterization and evidence for the identification of an active-site region in vertebrate a-ketoglutarate-dependent dioxygenases. Proc. Natl. Acad. Sci.1994;91:7227-7231.
[15]Gronke, R.S., W.J. VanDusen, V.M. Garsky, et al. Aspartyl b-hydroxylase:in vitro hydroxylation of a synthetic peptide based on the structure of the first growth factor-like domain of human factor IX. Proc. Natl. Acad. Sci.1989;86:3609-3613.
[16]Sunnerhagen MS, Persson E, Dahlqvist I, et al. The effect of aspartate hydroxylation on calcium binding to epidermal growth factor-like modules in coagulation factors IX and X. J. Biol. Chem.1993 Nov 5;268(31):23339-44.
[17]Stenflo, J., A. Lundwall, B. Dahlbach. B-Hydroxyasparagine in domains homologous to the epidermal growth factor precursor in vitamin K-dependent protein S. Proc. Natl. Acad. Sci. USA. 1987.84:368-372.
[18]Jhappan C, D.Gallahan C, Stahle, et al. Expression of an activated Notch-related int-3 transgene interferes with cell differentiation and induces neoplastic transformation in mammary and salivary glands. Genes Dev.1992.6:345-355.
[19]Stitt T.N., G. Conn, M. Gore, et al. The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro3/Axl family of receptor tyrosine kinases. Cell,1995,80:661-670.
[20]Joseph E. Dinchuk, Richard J. Focht, Jennifer A. Kelley. Absence of post-translational aspartyl-hydroxylation of epidermal growth factor domains in mice leads to developmental defects and an increased incidence of intestinal neoplasia. J. Biol.Chem.2002; 277(15):12970-12977.
[21]Cantarini MC, de la Monte SM, Pang M, Tong M, D'Errico A, Trevisani F, et al. Aspartyl-asparagyl beta hydroxylase overexpression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms. Hepatology 2006; 44:446-457.
[22]Luu M, Sabo E, de la Monte SM, Greaves W, Wang J, Tavares R, et al. Prognostic value of aspartyl (asparaginyl)-beta-hydroxylase/humbug expression in non-small cell lung carcinoma. Hum Pathol 2009; 40:639-644.
[23]Maeda T, Taguchi K, Aishima S, et al. Clinicopathological correlates of aspartyl (asparaginyl) beta-hydroxylase over-expression in cholangiocarcinoma. Cancer Detect Prev 2004;28:313-318.
[24]Lavaissiere.L, Jia S, Nishiyama M, et al. Overexpression of human aspartyl (asparaginyl) beta-hydroxylasein hepatocellular carcinoma and cholangiocarcinoma. J Clin Invest 1996;98:1313-1323.
[25]Talwalkar JA, Gores GJ. Diagnosis and staging of hepatocellular carcinoma. Gastroenterology 2004; 127:S126-S132.
[26]Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology.2002;35(3):519-524.
[27]de la Monte SM, Tamaki S, Cantarini MC, Ince N, Wiedmann M, Carter JJ, et al. Aspartyl-(asparaginyl)-beta-hydroxylase regulates hepatocellular carcinoma invasiveness. J Hepatol 2006; 44:971-983.
[28]Cantarini MC, de la Monte SM, Pang M, Tong M, D'Errico A, Trevisani F, et al. Aspartyl-asparagyl beta hydroxylase overexpression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms. Hepatology 2006; 44:446-457.
[29]Xian ZH, Zhang SH, Cong WM, Yan HX, Wang K, Wu MC. Expression of aspartyl beta-hydroxylase and its clinicopathologic significance in hepatocellular carcinoma. Mod Pathol 2006; 19:280-286.
[30]Torzilli,G,Donadon,M,Marconi,M,Palmisano,A,Del-Fabbro,D,Spinelli,A, et al. Hepatectomy for stage B and stage C hepatocellular carcinoma in the barcelona clinic liver cancer classification: results of a prospective analysis. Arch Surg 2008; 143:1082-1090.
[1]By Johan, Stenflo Structure-function relationships of epidermal growth factor modules in Vitamin K-dependent clotting factors. Blood 1991;78:1637-1651.
[2]Varnum BC, Young C, Elliott G, Garcia A, Bartley TD, Fridell YW, Hunt RW, Trail G, Clogston C,Toso RJ et al. Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6. Nature 1995; 373; 623～626.
[3]Villoutreix BO, Garcia de Frutos P, Lo" venklev M, LinseS, Fernlund P & Dahlba" ck B. SHBG region of the anticoagulant cofactor protein S:secondary structure prediction, circular dichroism spectroscopy,and analysis of naturally occurring mutations. Proteins.1997; 29; 478-491.
[4]Sasaki T, Knyazev PG, Clout NJ, et al. Structural basis for Gas6-Axl signalling. Embo J. 2006;25; 80～87.
[5]Melaragno MG, Cavet ME, Yan C, Tai LK, Jin ZG,Haendeler J & Berk BC. Gas6 inhibits apoptosis in vascular smooth muscle:role of Axl kinase and Akt. J Mol Cell Cardiol.2004; 37; 881-887.
[6]van Ginkel PR, Gee RL, Shearer RL, Subramanian L,Walker TM, Albert DM, Meisner LF, Varnum BC & Polans AS. Expression of the receptor tyrosine kinase Axl promotes ocular melanoma cell survival. Cancer Res.2004; 64; 128～134.
[7]Sainaghi PP, Castello L, Bergamasco L, Galletti M,Bellosta P & Avanzi GC. Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor. J Cell Physiol.2005; 204; 36～44.
[8]Demarchi F, Verardo R, Varnum B, Brancolini C, Schneider C. Gas6 anti-apoptotic signalling requires NF-kB activation. J Biol Chem.2001;276:31738～744.
[9]Yanagita M, Arai H, Nakano T, et al. Gas6 induces mesangial cell proliferation via latent transcription factor STAT3. J Biol Chem.2001;276:42364～42369.
[10]Craven RJ, Xu LH, Weiner TM, et al. Receptor tyrosine kinases expressed in metastatic colon cancer. Int J Cancer.1995;60; 791～807.
[11]Nemoto T, Ohashi K, Akashi T, Johnson JD, Hirokawa K. Overexpression of protein tyrosine kinases in human oesophageal cancer. Pathobiology.1997;65; 195～203.
[12]Ito M, NakashimaM, Nakayama T, et al. Expression of receptor-type tyrosine kinase, Axl, and its ligand, Gas6, in pediatric thyroid carcinomas around chernobyl. Thyroid.2002;12; 971～985.
[13]Zantek ND, Walker-Daniels J, Stewart J, et al. MCF-10A-NeoST:a new cell system for studying cell-ECM and cell-cell interactions in breast cancer. Clin Cancer Res.2001;7; 3640～3648.
[14]Shieh YS, Lai CY, Kao YR, et al. Expression of axl in lung adenocarcinoma and correlation with tumour progression. Neoplasia.2005;7; 1058～1064.
[15]Vajkoczy P, Knyazev P, Kunkel A, et al. Dominant-negative inhibition of the Axl receptor tyrosinekinase suppresses brain tumor cell growth and invasion and prolongs survival. Proc Natl Acad Sci USA.2006; 103; 5799～5804.
[16]Anna Gustafsson, DanutaMartuszewska, MartinJohansson, et al. Differential Expression of Axl and Gas6 in Renal Cell Carcinoma ReflectingTumorAdvancement and Survival Clin Cancer Res 2009;15(14); 4742-4749
[17]Ann-Ping Tsou, Keh-Ming Wu, Ten-Yen Tsen, et al. Parallel Hybridization Analysis of Multiple Protein Kinase Genes:Identification of Gene Expression Patterns Characteristic of Human Hepatocellular Carcinoma. Genomics 1998:50;331-340
[18]J P O'Bryan, R A Frye, P C Cogswell,et al axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol. Cell. Biol. 1991;11:5016-5031.
[19]Toru Nakamura, Isaiah J. Fidler, and Kevin R. Coombes Gene Expression Profile of Metastatic Human Pancreatic Cancer Cells Depends on the Organ Microenvironment. Cancer Res. 2007;67:139-148.
[20]Dahlback B & Villoutreix BO. Regulation of blood coagulation by the protein C anticoagulant pathway:novel insights into structure-function relationships and molecular recognition. Arterioscler Thromb Vasc Biol.2005; 25; 1311～1320.
[21]Wharton KA, Johansen KM, Artavanis-Tsakonas S. et al. Nucleotide sequence from the neurogenic locus notch implies a gene product that shares homology with proteins containing EGF-like repeats. Cell 1985;43:567-581.
[22]Downing, A. K., Knott, V., Werner, et al. Solution structure of a pair of calcium-binding epidermal growth factor-like domains:implications for the Marfan syndrome and other genetic disorders. Cell,1996,85:597-605.
[23]Stenflo, J., A. Lundwall, B. Dahlbach. b-Hydroxyasparagine in domains homologous to the epidermal growth factor precursor in vitamin K-dependent protein S. Proc. Natl. Acad. Sci. USA. 1987.84:368-372.
[24]Stenflo, J. Structure-function relationship of epidermal growth factor modules in vitamin-K dependent clotting factors. Blood,1991,78:1637-1651.
[25]Goruppi, S., Yamane, H., Marcandalli, P. The product of a gas6 splice variant allows the release of the domain responsible for Axl tyrosine kinase receptor activation.FEBS Lett.1997 Sep 22;415(1):59-63.
[26]Stitt T.N., G. Conn, M. Gore, et al. The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro3/Axl family of receptor tyrosine kinases. Cell,1995,80:661-670.
[27]Rebay, I., Fleming, R. J, Fehon, R. G, et al. Specific EGF repeats of Notch mediate interactions with Delta and Serrate:implications for Notch as a multifunctional receptor.Cell, 1991,67:687-699.
[28]Lawrence N, Klein T, Brennan K.Structural requirements for notch signalling with delta and serrate during the development and patterning of the wing disc of Drosophila. Development 2000 Jul;127(14):3185-95.
[29]Jia, S., K. McGinnis, W.J. VanDusen, et al. A fully active catalytic domain of bovine aspartyl (asparaginyl)β-hydroxylase expressed in Escherichia coli:characterization and evidence for the identification of an active-site region in vertebrate a-ketoglutarate-dependent dioxygenases. Proc.Natl.Acad.Sci. USA,1994,91:7227-7231.
[30]Gronke, R.S., W.J. VanDusen, V.M. Garsky, et al. Aspartyl-β-hydroxylase:in vitro hydroxylation of a synthetic peptide based on the structure of the first growth factor-like domain of human factor IX. Proc. Natl. Acad.Sci. USA.1989;86:3609-3613.
[31]Sunnerhagen MS, Persson E, Dahlqvist I, et al.The effect of aspartate hydroxylation on calcium binding to epidermal growth factor-like modules in coagulation factors IX and X. J. Biol. Chem.1993 Nov 5;268(31):23339-44.
[1]Bosch FX, Ribes J, Diaz M, et al. Primary liver cancer:worldwide incidence and trends. Gastroenterology 2004(suppl 1);127:5-16.
[2]Yang L, Parkin DM, Whelan S, et al. Statistics on cancer in China:cancer registration in 2002. Eur J Cancer Prev 2005;14:329-335.
[3]Portolani N, Coniglio A, Ghidoni S, et al. Early and late recurrence after liver resection for hepatocellular carcinoma:prognostic and therapeutic implications. Ann Surg 2006;243:229-235.
[4]Bruix J, Boix L, Sala M, et al. Focus on hepatocellular carcinoma. Cancer Cell 2004;5:215-219.
[5]Poon RT, Fan ST, Lo CM, et al. Intrahepatic recurrence after curative resection of. hepatocellular carcinoma:long-term results of treatment and prognostic factors. Ann Surg 1999;229:216-222.
[6]Shimozawa N, Hanazaki K:Long term prognosis after hepatic resection for small hepatocellular Carcinoma. J Am Coll Surg 2004;198:356-365.
[7]Bruix J, Sherman M:Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236.
[8]Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-430.
[9]Llovet JM, Bruix J:Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008(suppl 1);48:20-37.
[10]Izumi R, Shimizu K, Ii T, et al. Prognostic factors of hepatocellular carcinoma in patient undergoing hepatic resection. Gastroenterology 1994; 106:720-727.
[11]Iizuka N, Oka M, Yamada-Okabe H, et al. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet 2003;361:923-939.
[12]Minagawa M, Ikai I, Matsuyama Y, et al. Staging of hepatocellular carcinoma:assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg 2007;245:909-922.
[13]Hoshida Y, Villanueva A, Kobayashi M, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008;359:1995-2004.
[14]Wharton KA, Johansen KM, Artavanis-Tsakonas S. et al. Nucleotide sequence from the neurogenic locus notch implies a gene product that shares homology with proteins containing EGF-like repeats. Cell 1985;43:567-581.
[15]Downing, A. K., Knott, V., Werner, et al. Solution structure of a pair of calcium-binding epidermal growth factor-like domains:implications for the Marfan syndrome and other genetic disorders. Cell,1996,85:597-605.
[16]Blaumueller CM, Qi H, Artavanis-Tsakonas S. et al Intracellular cleavage of Notch leads to a heterodimeric receptor on the plasma membrane. Cell.1997;90:281-291.
[17]Mumm JS, Kopan R. Notch signaling:from the outside in. Dev Biol 2000;228:151-165.
[18]Fan X, Matsui W, Khaki L, et al. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res 2006;66:7445-7452.
[19]Weng AP, Aster JC:Multiple niches for Notch in cancer:context is everything. Current Opinion Genet Dev 2004; 14:48-54.
[20]Noseda M, Chang L, McLean G, et al. Notch activation induces endothelial cell cycle arrest and participates in contact inhibition:Role of p21Cipl repression. Mol Cell Biol 2004;24:8813-8822.
[21]Dufraine J, Funahashi Y, Kitajewski J:Notch signaling regulates tumor angiogenesis by diverse mechanisms. Oncogene 2008;27;5132-5137.
[22]Qi R, An H, Yu Y, et al. Notchl signaling inhibits growth of human hepatocellular carcinoma through induction of cell cycle arrest and apoptosis. Cancer Res 2003;63:8323-8329.
[23]Wang C, Qi R, Li N, et al. Notchl signaling sensitizes TRAIL-induced apoptosis in human hepatocellular carcinoma cells by inhibiting Akt/Hdm2-mediated p53 degradation and up-regulating p53-dependent DR5 expression. J Biol Chem 2009;284:16183-16190.
[24]Cantarini MC, de la Monte SM, Pang M, et al. Aspartyl-asparagyl beta hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms. Hepatology 2006;44:446-457.
[25]Joseph E. Dinchuk, Richard J. Focht, Jennifer A. Kelley. Absence of post-translational aspartyl-β-hydroxylation of epidermal growth factor domains in mice leads to developmental defects and an increased incidence of intestinal neoplasia. J. Biol.Chem.2002; 277 (15):12970-12977.
[26]Dontu G, Jackson KW, McNicholas E, et al. Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res 2004;6:605-615.
[27]Kevin G. Leong, Xiaolong Hu, Linheng Li, Michela Noseda, Bruno Larrivee, Christopher Hull, et al. Activated Notch4 Inhibits Angiogenesis:Role of β1-Integrin Activation. Mol. Cell. Biol.2002; 22:2830-2841.
[28]Weng AP, Aster JC:Multiple niches for Notch in cancer:context is everything. Current Opinion Genet Dev 2004;14:48-54.
[29]Talwalkar JA, Gores GJ:Diagnosis and "staging of hepatocellular carcinoma. Gastroenterology 2004(suppl 1);127:126-132.
[30]Leong KG, Niessen K, Kulic I, et al. Jaggedl-mediated Notch activation induces epithelial-to-mesenchymal transition through Slug-induced repression of E-cadherin. J Exp Med 2007;204:2935-2948.
[31]Sobin LH, Wittekind C (eds):TNM Classification of Malignant Tumors (ed 6). New York, NY, Wiley-Liss,2002, pp 81-83
[32]Yamamoto J, Kosuge T, Saiura A, et al. Effectiveness of hepatic resection for early-stage hepatocellular carcinoma in cirrhotic patients:Subgroup analysis according to Milan criteria. Jpn J Clin Oncol 2007;37:287-295.
[33]Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-699.
[34]Vauthey JN, Lauwers GY, Esnaola NF, et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol 2002;20:1527-36.
[1]Wharton KA, Johansen KM, Artavanis-Tsakonas S. et al Nucleotide sequence from the neurogenic locus notch implies a gene product that shares homology with proteins containing EGF-like repeats. Cell 1985;43:567-581.
[2]Blaumueller CM, Qi H, Artavanis-Tsakonas S. et al Intracellular cleavage of Notch leads to a heterodimeric receptor on the plasma membrane. Cell 1997;90:281-291.
[3]Matthew D. Rand, Calcium depletion dissociates and activates heterodimeric Notch receptors. Mol Cell Biol, Mar.2000; 1825-1835.
[4]Mumm JS, Kopan R. Notch signaling:from the outside in. Dev Biol.2000;228:151-165.
[5]Edbauer D, Winkler E, Haass C. et al Reconstitution of gamma—secretase activity. Nat Cell Biol.2003;5:486-488.
[6]Iso T, Kedes L, Hamamori Y. HES and HERP families:multiple effectors of the Notch signaling pathway. J Cell Physiol.2003;194:237-255.
[7]Martinex Arias A,Zecchini V.Brennan K, CSL-independent Notch signalling:a checkpoint in cell fate decisions during development? Curr Opin Genet Dev 2002,12:524-533
[8]S Fre, M Huyghe, P Mourikis S Artavanis-Tsakonas et al Notch signals control the fate of immature progenitor cells in the intestine. Nature 2005; 435(7044):964-8
[9]JH van Es, ME van Gijn, H Clevers et al Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 2005; 435(7044): 959-63.
[101 Ellisen LW, Bird J, West DC et al TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 1991;66:649-661.
[11]AAndroutsellis-Theotokis, RR Leker, RD McKay et al Notch signaling regulates stem cell numbers in vitro and in vivo. Nature 2006; 442(7104):823-6.
[12]Nicolas M., Wolfer, Radtke F. et al Notchl functions as a tumor suppressor in mouse skin. Nat Genet.2003;33:416-421.
[13]Vauclair S., Nicolas, M., Radtke, F. et al Notchl is essential for postnatal hair follicle development and homeostasis. Dev. Biol.2005;284:184-193.
[14]Yamamoto N., Tanigaki K., and Honjo T. et al Notch/RBP-J signaling regulates epidermis/hair fate determination of hair follicular stem cells. Curr. Biol.2003; 13:333-338.
[15]Pan Y., Lin M.H. and Kopan R. et al gamma-secretase functions through Notch signaling to maintain skin appendages but is not required for their patterning or initial morphogenesis. Dev. Cell 2004;7:731-743.
[16]Devgan V., Mammucari C., Dotto G.P. et al p21WAF1/Cipl is a negative transcriptional regulator of Wnt4 expression downstream of Notchl activation. Genes Dev.2005;19:1485-1495.
[17]Karine Lefort, Anna Mandinova, G. Paolo Dotto et al Notchl is a p53 target gene involved in human keratinocyte tumor suppression through negative regulation of ROCK1/2 and MRCK(?) kinases Genes & Dev.2007; 21:562-577.
[18]Monzani E, Facchetti F, La Porta CA et al Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer.2007;43(5):935-46
[19]Croquelois A, Blindenbacher A, Terracciano L et al Inducible inactivation of Notchl causes nodular regenerative hyperplasia in mice. Hepatology 2005;41:487-496.
[20]Runzi Qi, Xuetao Cao et al Notchl signaling inhibits growth of human hepatocellular crcinoma through induction of cell cycle arrest and apoptosis. Cancer Res 2003; 63:8323-8329.
[21]M. Chiara Cantarini, Jack R. Wands et al Aspartyl-Asparagyl hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and Notch signaling mechanisms. Hepatology 2006;44:446-457.
[22]J Gao, C Chen, D Fan et al Expression of Jagged1 and its association with hepatitis B virus X protein in hepatocellular carcinoma. Biochem Biophys Res Commun 2007; 356(2):341-7.
[23]Jian Huang, Xin Zhang, Ze-Guang Han et al Up-regulation of DLK1 as an imprinted gene could contribute to human hepatocellular carcinoma.Carcinogenesis 2007; 28:1094-1103.
[24]Purow BW, Haque RM, Noel MW, et al. Expression of Notchl and its ligands, Delta— likel and Jaggedl, is critical for glioma cell survival and proliferation. Cancer Res.2005; 65 (6):2353-2363.
[25]Okano H, Imai T, Okabe M et al Musashi:a translational regulator of cell fate. J Cell Sci. 2002;115:1355-1359.
[26]Xing Fan, Irina Mikolaenko, G. Eberhart et al Notchl and Notch2 have opposite effects on embryonal brain tumor growth. Cancer Res 2004;64:7787-7793.
[27]Imatani A, Callahan R. et al Identification of a novel NOTCH-4/INT-3 RNA species encoding an activated gene product in certain human tumor cell lines. Oncogene 2000;19:223-231.
[28]Weij S, Rizzo P, Braid M, et al. Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med.2002;8:979-986.
[29]Parr C, Watkins G, Jiang WG. et al The possible correlation of Notch-1 and Notch-2 with clinical outcome and tumour clinicopathological parameters in human breast cancer. Int J Mol Med.2004;14:779-786.
[30]Dickson BC, Mulligan AM, Reedijk M et al High-level JAG1 mRNA and protein predict poor outcome in breast cancer. Mod Pathol.2007;20(6):685-93.
[31]S Liu, G Dontu, and MS Wicha Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Res 2005; 7(3):86-95.
[32]Curry CL, Reed LL, Foreman KE. et al Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells. Oncogene.2005;24:6333-6344.
[33]Anna Bigas, David I. K. Martin,and Laurie A. Milner Notchl and Notch2 Inhibit Myeloid Differentiation in Response to Different Cytokines Mol Cell Biol,1998;18:2324-2333.
[34]Guan E, Wang J, Hoffman T. et al T cell leukemia-associated human Notch/translocation-associated Notch homologue has I kappa B-like activity and physically interacts with nuclear factor-kappa B proteins in T cells. J Exp Med.1996;183:2025-2032.
[2]Tang ZY. Hepatocellular carcinoma-Cause, treatment and metastasis. World J Gastroenterol 2001; 7:445-454.
[3]Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio GA, et al. Early and late recurrence after liver resection for hepatocellular carcinoma:prognostic and therapeutic implications. Ann Surg 2006; 243:229-235.
[4]Bruix J, Boix L, Sala M, Llovet JM. Focus on hepatocellular carcinoma. Cancer Cell 2004; 5:215-219.
[5]Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Intrahepatic recurrence after curative resection of hepatocellular carcinoma:long-term results of treatment and prognostic factors. Ann Surg 1999; 229:216-222.
[6]Sobin LH,Wittekind C.TNM classification of malignant tumors,6th edition. New York:UICC, Wiley-Liss,2002:81-83.
[7]Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R,Andrew K,et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001; 35:421-430.
[8]Bruix J,Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42:1208-1236.
[9]Grieco A, Pompili M, Caminiti G, Miele L, Covino M, Alfei B, et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy:comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut 2005; 54:411-418.
[10]Minagawa M, Ikai I, Matsuyama Y, Yamaoka Y, Makuuchi M. Staging of hepatocellular carcinoma:assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg 2007; 245:909-922.
[11]Yoon SK. Recent advances in tumor markers of human hepatocellular carcinoma. Intervirology.2008; 51(suppl 1):34-41.
[12]Downing, A. K., Knott, V., Werner, et al. Solution structure of a pair of calcium-binding epidermal growth factor-like domains:implications for the Marfan syndrome and other genetic disorders. Cell,1996;85:597-605.
[13]Lawrence N, Klein T, Brennan K. Structural requirements for notch signalling with delta and serrate during the development and patterning of the wing disc of Drosophila. Development 2000 Jul;127(14):3185-95.
[14]Ince N, de la Monte SM, Wands JR. Overexpression of human aspartyl (asparaginyl) beta-hydroxylase is associated with malignant transformation. Cancer Res 2000;60:1261-1266.
[15]Schena Mt Shalon D, Dais R W, et al. Quantitative monitoring of gene expression patterns with a complementary DNA microarrays. Science,1995;270(20):467-470.
[16]Gronke, R.S., D.J. Welsch, W.J. Van Dusen, et al. Partial purification and characterization of bovine liver aspartyl-β-hydroxylase. J.Biol.Chem.1990; 265:8558-8565.
[17]Frank Korioth, Christian Gieffers and Jiirgen Frey. Cloning and characterization of the human gene encoding aspartyl-β-hydroxylase. Gene 1994;150:395-399.
[18]Susan Treves, Giordana Feriotto, Luca Moccagatta. Molecular cloning, expression, functional characterization, chromosomal localization, and gene structure of junctate, a novel integral calcium binding protein of sarco(endo) plasmic reticulum membrane. J. Biol.Chem 2000;275(50):39555-39568.
[19]Jia, S, W.J. Van Dusen, R.E. Diehl, et al. cDNA cloning and expression of bovine aspartyl(asparaginyl)-β-hydroxylase. J. Biol. Chem.1992;267:14322-14327.
[20]Jia, S., K. McGinnis, W.J. VanDusen, et al. A fully active catalytic domain of bovine aspartyl(asparaginyl)-β-hydroxylase expressed in Escherichia coli:characterization and evidence for the identification of an active-site region in vertebrate a-ketoglutarate-dependent dioxygenases. Proc. Natl. Acad. Sci.1994;91:7227-7231.
[21]Gronke, R.S., W.J. VanDusen, V.M. Garsky, et al. Aspartyl b-hydroxylase:in vitro hydroxylation of a synthetic peptide based on the structure of the first growth factor-like domain of human factor IX. Proc. Natl. Acad. Sci.1989;86:3609-3613.
[22]Sunnerhagen MS, Persson E, Dahlqvist I, et al. The effect of aspartate hydroxylation on calcium binding to epidermal growth factor-like modules in coagulation factors IX and X. J. Biol. Chem.1993 Nov 5;268(31):23339-44.
[23]Stenflo, J., A. Lundwall, B. Dahlbach.β-Hydroxyasparagine in domains homologous to the epidermal growth factor precursor in vitamin K-dependent protein S. Proc. Natl. Acad. Sci. USA. 1987.84:368-372.
[24]Jhappan C, D.Gallahan C, Stahle, et al. Expression of an activated Notch-related int-3 transgene interferes with cell differentiation and induces neoplastic transformation in mammary and salivary glands. Genes Dev.1992.6:345-355.
[25]Stitt T.N., G. Conn, M. Gore, et al. The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro3/Axl family of receptor tyrosine kinases. Cell,1995,80:661-670.
[26]Joseph E. Dinchuk, Richard J. Focht, Jennifer A. Kelley. Absence of post-translational aspartyl-hydroxylation of epidermal growth factor domains in mice leads to developmental defects and an increased incidence of intestinal neoplasia. J. Biol.Chem.2002; 277(15):12970-12977.
[27]Cantarini MC, de la Monte SM, Pang M, Tong M, D'Errico A, Trevisani F, et al. Aspartyl-asparagyl beta hydroxylase overexpression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms. Hepatology 2006; 44:446-457.
[28]Luu M, Sabo E, de la Monte SM, Greaves W, Wang J, Tavares R, et al. Prognostic value of aspartyl (asparaginyl)-beta-hydroxylase/humbug expression in non-small cell lung carcinoma. Hum Pathol 2009; 40:639-644.
[29]Maeda T, Taguchi K, Aishima S, et al. Clinicopathological correlates of aspartyl (asparaginyl) beta-hydroxylase over-expression in cholangiocarcinoma. Cancer Detect Prev 2004;28:313-318.
[30]Lavaissiere.L, Jia S, Nishiyama M, et al. Overexpression of human aspartyl (asparaginyl) beta-hydroxylasein hepatocellular carcinoma and cholangiocarcinoma. J Clin Invest 1996;98:1313-1323.
[1]Bruix J,Sherman M.Management of hepatocellular carcinoma. Hepatology 2005; 42:1208-1236.
[2]Sobin LH,Wittekind C.TNM classification of malignant tumors,6th edition. New York:UICC, Wiley-Liss,2002:81-83.
[3]Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R,Andrew K,et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001; 35:421-430.
[4]Edmondson HA, Steiner PE. Primary carcinoma of the liver:A study of 100 cases among 48,900 necropsies. Cancer 1954:7; 462-503.
[5]Llovet JM, di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX et al. Design and endpoints of clinical Trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100:698-711.
[6]Downing, A. K., Knott, V., Werner, et al. Solution structure of a pair of calcium-binding epidermal growth factor-like domains:implications for the Marfan syndrome and other genetic disorders. Cell,1996;85:597-605.
[7]Lawrence N, Klein T, Brennan K. Structural requirements for notch signalling with delta and serrate during the development and patterning of the wing disc of Drosophila. Development 2000 Jul;127(14):3185-95.
[8]Ince N, de la Monte SM, Wands JR. Overexpression of human aspartyl (asparaginyl) beta-hydroxylase is associated with malignant transformation. Cancer Res 2000;60:1261-1266.
[9]Schena Mt Shalon D, Dais R W, et al. Quantitative monitoring of gene expression patterns with a complementary DNA microarrays. Science,1995;270(20):467-470.
[10]Gronke, R.S., D.J. Welsch, W.J. Van Dusen, et al. Partial purification and characterization of bovine liver aspartyl-B-hydroxylase. J.Biol.Chem.1990; 265:8558-8565.
[11]Frank Korioth, Christian Gieffers and Jiirgen Frey. Cloning and characterization of the human gene encoding aspartyl-β-hydroxylase. Gene 1994;150:395-399.
[12]Susan Treves, Giordana Feriotto, Luca Moccagatta. Molecular cloning, expression, functional characterization, chromosomal localization, and gene structure of junctate, a novel integral calcium binding protein of sarco(endo) plasmic reticulum membrane. J. Biol.Chem 2000;275(50):39555-39568.
[13]Jia, S, W.J. Van Dusen, R.E. Diehl, et al. cDNA cloning and expression of bovine aspartyl(asparaginyl)-β-hydroxylase. J. Biol. Chem.1992;267:14322-14327.
[14]Jia, S., K. McGinnis, W.J. VanDusen, et al. A fully active catalytic domain of bovine aspartyl(asparaginyl)-β-hydroxylase expressed in Escherichia coli:characterization and evidence for the identification of an active-site region in vertebrate a-ketoglutarate-dependent dioxygenases. Proc. Natl. Acad. Sci.1994;91:7227-7231.
[15]Gronke, R.S., W.J. VanDusen, V.M. Garsky, et al. Aspartyl b-hydroxylase:in vitro hydroxylation of a synthetic peptide based on the structure of the first growth factor-like domain of human factor IX. Proc. Natl. Acad. Sci.1989;86:3609-3613.
[16]Sunnerhagen MS, Persson E, Dahlqvist I, et al. The effect of aspartate hydroxylation on calcium binding to epidermal growth factor-like modules in coagulation factors IX and X. J. Biol. Chem.1993 Nov 5;268(31):23339-44.
[17]Stenflo, J., A. Lundwall, B. Dahlbach. B-Hydroxyasparagine in domains homologous to the epidermal growth factor precursor in vitamin K-dependent protein S. Proc. Natl. Acad. Sci. USA. 1987.84:368-372.
[18]Jhappan C, D.Gallahan C, Stahle, et al. Expression of an activated Notch-related int-3 transgene interferes with cell differentiation and induces neoplastic transformation in mammary and salivary glands. Genes Dev.1992.6:345-355.
[19]Stitt T.N., G. Conn, M. Gore, et al. The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro3/Axl family of receptor tyrosine kinases. Cell,1995,80:661-670.
[20]Joseph E. Dinchuk, Richard J. Focht, Jennifer A. Kelley. Absence of post-translational aspartyl-hydroxylation of epidermal growth factor domains in mice leads to developmental defects and an increased incidence of intestinal neoplasia. J. Biol.Chem.2002; 277(15):12970-12977.
[21]Cantarini MC, de la Monte SM, Pang M, Tong M, D'Errico A, Trevisani F, et al. Aspartyl-asparagyl beta hydroxylase overexpression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms. Hepatology 2006; 44:446-457.
[22]Luu M, Sabo E, de la Monte SM, Greaves W, Wang J, Tavares R, et al. Prognostic value of aspartyl (asparaginyl)-beta-hydroxylase/humbug expression in non-small cell lung carcinoma. Hum Pathol 2009; 40:639-644.
[23]Maeda T, Taguchi K, Aishima S, et al. Clinicopathological correlates of aspartyl (asparaginyl) beta-hydroxylase over-expression in cholangiocarcinoma. Cancer Detect Prev 2004;28:313-318.
[24]Lavaissiere.L, Jia S, Nishiyama M, et al. Overexpression of human aspartyl (asparaginyl) beta-hydroxylasein hepatocellular carcinoma and cholangiocarcinoma. J Clin Invest 1996;98:1313-1323.
[25]Talwalkar JA, Gores GJ. Diagnosis and staging of hepatocellular carcinoma. Gastroenterology 2004; 127:S126-S132.
[26]Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology.2002;35(3):519-524.
[27]de la Monte SM, Tamaki S, Cantarini MC, Ince N, Wiedmann M, Carter JJ, et al. Aspartyl-(asparaginyl)-beta-hydroxylase regulates hepatocellular carcinoma invasiveness. J Hepatol 2006; 44:971-983.
[28]Cantarini MC, de la Monte SM, Pang M, Tong M, D'Errico A, Trevisani F, et al. Aspartyl-asparagyl beta hydroxylase overexpression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms. Hepatology 2006; 44:446-457.
[29]Xian ZH, Zhang SH, Cong WM, Yan HX, Wang K, Wu MC. Expression of aspartyl beta-hydroxylase and its clinicopathologic significance in hepatocellular carcinoma. Mod Pathol 2006; 19:280-286.
[30]Torzilli,G,Donadon,M,Marconi,M,Palmisano,A,Del-Fabbro,D,Spinelli,A, et al. Hepatectomy for stage B and stage C hepatocellular carcinoma in the barcelona clinic liver cancer classification: results of a prospective analysis. Arch Surg 2008; 143:1082-1090.
[1]By Johan, Stenflo Structure-function relationships of epidermal growth factor modules in Vitamin K-dependent clotting factors. Blood 1991;78:1637-1651.
[2]Varnum BC, Young C, Elliott G, Garcia A, Bartley TD, Fridell YW, Hunt RW, Trail G, Clogston C,Toso RJ et al. Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6. Nature 1995; 373; 623～626.
[3]Villoutreix BO, Garcia de Frutos P, Lo" venklev M, LinseS, Fernlund P & Dahlba" ck B. SHBG region of the anticoagulant cofactor protein S:secondary structure prediction, circular dichroism spectroscopy,and analysis of naturally occurring mutations. Proteins.1997; 29; 478-491.
[4]Sasaki T, Knyazev PG, Clout NJ, et al. Structural basis for Gas6-Axl signalling. Embo J. 2006;25; 80～87.
[5]Melaragno MG, Cavet ME, Yan C, Tai LK, Jin ZG,Haendeler J & Berk BC. Gas6 inhibits apoptosis in vascular smooth muscle:role of Axl kinase and Akt. J Mol Cell Cardiol.2004; 37; 881-887.
[6]van Ginkel PR, Gee RL, Shearer RL, Subramanian L,Walker TM, Albert DM, Meisner LF, Varnum BC & Polans AS. Expression of the receptor tyrosine kinase Axl promotes ocular melanoma cell survival. Cancer Res.2004; 64; 128～134.
[7]Sainaghi PP, Castello L, Bergamasco L, Galletti M,Bellosta P & Avanzi GC. Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor. J Cell Physiol.2005; 204; 36～44.
[8]Demarchi F, Verardo R, Varnum B, Brancolini C, Schneider C. Gas6 anti-apoptotic signalling requires NF-kB activation. J Biol Chem.2001;276:31738～744.
[9]Yanagita M, Arai H, Nakano T, et al. Gas6 induces mesangial cell proliferation via latent transcription factor STAT3. J Biol Chem.2001;276:42364～42369.
[10]Craven RJ, Xu LH, Weiner TM, et al. Receptor tyrosine kinases expressed in metastatic colon cancer. Int J Cancer.1995;60; 791～807.
[11]Nemoto T, Ohashi K, Akashi T, Johnson JD, Hirokawa K. Overexpression of protein tyrosine kinases in human oesophageal cancer. Pathobiology.1997;65; 195～203.
[12]Ito M, NakashimaM, Nakayama T, et al. Expression of receptor-type tyrosine kinase, Axl, and its ligand, Gas6, in pediatric thyroid carcinomas around chernobyl. Thyroid.2002;12; 971～985.
[13]Zantek ND, Walker-Daniels J, Stewart J, et al. MCF-10A-NeoST:a new cell system for studying cell-ECM and cell-cell interactions in breast cancer. Clin Cancer Res.2001;7; 3640～3648.
[14]Shieh YS, Lai CY, Kao YR, et al. Expression of axl in lung adenocarcinoma and correlation with tumour progression. Neoplasia.2005;7; 1058～1064.
[15]Vajkoczy P, Knyazev P, Kunkel A, et al. Dominant-negative inhibition of the Axl receptor tyrosinekinase suppresses brain tumor cell growth and invasion and prolongs survival. Proc Natl Acad Sci USA.2006; 103; 5799～5804.
[16]Anna Gustafsson, DanutaMartuszewska, MartinJohansson, et al. Differential Expression of Axl and Gas6 in Renal Cell Carcinoma ReflectingTumorAdvancement and Survival Clin Cancer Res 2009;15(14); 4742-4749
[17]Ann-Ping Tsou, Keh-Ming Wu, Ten-Yen Tsen, et al. Parallel Hybridization Analysis of Multiple Protein Kinase Genes:Identification of Gene Expression Patterns Characteristic of Human Hepatocellular Carcinoma. Genomics 1998:50;331-340
[18]J P O'Bryan, R A Frye, P C Cogswell,et al axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol. Cell. Biol. 1991;11:5016-5031.
[19]Toru Nakamura, Isaiah J. Fidler, and Kevin R. Coombes Gene Expression Profile of Metastatic Human Pancreatic Cancer Cells Depends on the Organ Microenvironment. Cancer Res. 2007;67:139-148.
[20]Dahlback B & Villoutreix BO. Regulation of blood coagulation by the protein C anticoagulant pathway:novel insights into structure-function relationships and molecular recognition. Arterioscler Thromb Vasc Biol.2005; 25; 1311～1320.
[21]Wharton KA, Johansen KM, Artavanis-Tsakonas S. et al. Nucleotide sequence from the neurogenic locus notch implies a gene product that shares homology with proteins containing EGF-like repeats. Cell 1985;43:567-581.
[22]Downing, A. K., Knott, V., Werner, et al. Solution structure of a pair of calcium-binding epidermal growth factor-like domains:implications for the Marfan syndrome and other genetic disorders. Cell,1996,85:597-605.
[23]Stenflo, J., A. Lundwall, B. Dahlbach. b-Hydroxyasparagine in domains homologous to the epidermal growth factor precursor in vitamin K-dependent protein S. Proc. Natl. Acad. Sci. USA. 1987.84:368-372.
[24]Stenflo, J. Structure-function relationship of epidermal growth factor modules in vitamin-K dependent clotting factors. Blood,1991,78:1637-1651.
[25]Goruppi, S., Yamane, H., Marcandalli, P. The product of a gas6 splice variant allows the release of the domain responsible for Axl tyrosine kinase receptor activation.FEBS Lett.1997 Sep 22;415(1):59-63.
[26]Stitt T.N., G. Conn, M. Gore, et al. The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro3/Axl family of receptor tyrosine kinases. Cell,1995,80:661-670.
[27]Rebay, I., Fleming, R. J, Fehon, R. G, et al. Specific EGF repeats of Notch mediate interactions with Delta and Serrate:implications for Notch as a multifunctional receptor.Cell, 1991,67:687-699.
[28]Lawrence N, Klein T, Brennan K.Structural requirements for notch signalling with delta and serrate during the development and patterning of the wing disc of Drosophila. Development 2000 Jul;127(14):3185-95.
[29]Jia, S., K. McGinnis, W.J. VanDusen, et al. A fully active catalytic domain of bovine aspartyl (asparaginyl)β-hydroxylase expressed in Escherichia coli:characterization and evidence for the identification of an active-site region in vertebrate a-ketoglutarate-dependent dioxygenases. Proc.Natl.Acad.Sci. USA,1994,91:7227-7231.
[30]Gronke, R.S., W.J. VanDusen, V.M. Garsky, et al. Aspartyl-β-hydroxylase:in vitro hydroxylation of a synthetic peptide based on the structure of the first growth factor-like domain of human factor IX. Proc. Natl. Acad.Sci. USA.1989;86:3609-3613.
[31]Sunnerhagen MS, Persson E, Dahlqvist I, et al.The effect of aspartate hydroxylation on calcium binding to epidermal growth factor-like modules in coagulation factors IX and X. J. Biol. Chem.1993 Nov 5;268(31):23339-44.
[1]Bosch FX, Ribes J, Diaz M, et al. Primary liver cancer:worldwide incidence and trends. Gastroenterology 2004(suppl 1);127:5-16.
[2]Yang L, Parkin DM, Whelan S, et al. Statistics on cancer in China:cancer registration in 2002. Eur J Cancer Prev 2005;14:329-335.
[3]Portolani N, Coniglio A, Ghidoni S, et al. Early and late recurrence after liver resection for hepatocellular carcinoma:prognostic and therapeutic implications. Ann Surg 2006;243:229-235.
[4]Bruix J, Boix L, Sala M, et al. Focus on hepatocellular carcinoma. Cancer Cell 2004;5:215-219.
[5]Poon RT, Fan ST, Lo CM, et al. Intrahepatic recurrence after curative resection of. hepatocellular carcinoma:long-term results of treatment and prognostic factors. Ann Surg 1999;229:216-222.
[6]Shimozawa N, Hanazaki K:Long term prognosis after hepatic resection for small hepatocellular Carcinoma. J Am Coll Surg 2004;198:356-365.
[7]Bruix J, Sherman M:Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236.
[8]Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-430.
[9]Llovet JM, Bruix J:Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008(suppl 1);48:20-37.
[10]Izumi R, Shimizu K, Ii T, et al. Prognostic factors of hepatocellular carcinoma in patient undergoing hepatic resection. Gastroenterology 1994; 106:720-727.
[11]Iizuka N, Oka M, Yamada-Okabe H, et al. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet 2003;361:923-939.
[12]Minagawa M, Ikai I, Matsuyama Y, et al. Staging of hepatocellular carcinoma:assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg 2007;245:909-922.
[13]Hoshida Y, Villanueva A, Kobayashi M, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008;359:1995-2004.
[14]Wharton KA, Johansen KM, Artavanis-Tsakonas S. et al. Nucleotide sequence from the neurogenic locus notch implies a gene product that shares homology with proteins containing EGF-like repeats. Cell 1985;43:567-581.
[15]Downing, A. K., Knott, V., Werner, et al. Solution structure of a pair of calcium-binding epidermal growth factor-like domains:implications for the Marfan syndrome and other genetic disorders. Cell,1996,85:597-605.
[16]Blaumueller CM, Qi H, Artavanis-Tsakonas S. et al Intracellular cleavage of Notch leads to a heterodimeric receptor on the plasma membrane. Cell.1997;90:281-291.
[17]Mumm JS, Kopan R. Notch signaling:from the outside in. Dev Biol 2000;228:151-165.
[18]Fan X, Matsui W, Khaki L, et al. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res 2006;66:7445-7452.
[19]Weng AP, Aster JC:Multiple niches for Notch in cancer:context is everything. Current Opinion Genet Dev 2004; 14:48-54.
[20]Noseda M, Chang L, McLean G, et al. Notch activation induces endothelial cell cycle arrest and participates in contact inhibition:Role of p21Cipl repression. Mol Cell Biol 2004;24:8813-8822.
[21]Dufraine J, Funahashi Y, Kitajewski J:Notch signaling regulates tumor angiogenesis by diverse mechanisms. Oncogene 2008;27;5132-5137.
[22]Qi R, An H, Yu Y, et al. Notchl signaling inhibits growth of human hepatocellular carcinoma through induction of cell cycle arrest and apoptosis. Cancer Res 2003;63:8323-8329.
[23]Wang C, Qi R, Li N, et al. Notchl signaling sensitizes TRAIL-induced apoptosis in human hepatocellular carcinoma cells by inhibiting Akt/Hdm2-mediated p53 degradation and up-regulating p53-dependent DR5 expression. J Biol Chem 2009;284:16183-16190.
[24]Cantarini MC, de la Monte SM, Pang M, et al. Aspartyl-asparagyl beta hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms. Hepatology 2006;44:446-457.
[25]Joseph E. Dinchuk, Richard J. Focht, Jennifer A. Kelley. Absence of post-translational aspartyl-β-hydroxylation of epidermal growth factor domains in mice leads to developmental defects and an increased incidence of intestinal neoplasia. J. Biol.Chem.2002; 277 (15):12970-12977.
[26]Dontu G, Jackson KW, McNicholas E, et al. Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res 2004;6:605-615.
[27]Kevin G. Leong, Xiaolong Hu, Linheng Li, Michela Noseda, Bruno Larrivee, Christopher Hull, et al. Activated Notch4 Inhibits Angiogenesis:Role of β1-Integrin Activation. Mol. Cell. Biol.2002; 22:2830-2841.
[28]Weng AP, Aster JC:Multiple niches for Notch in cancer:context is everything. Current Opinion Genet Dev 2004;14:48-54.
[29]Talwalkar JA, Gores GJ:Diagnosis and "staging of hepatocellular carcinoma. Gastroenterology 2004(suppl 1);127:126-132.
[30]Leong KG, Niessen K, Kulic I, et al. Jaggedl-mediated Notch activation induces epithelial-to-mesenchymal transition through Slug-induced repression of E-cadherin. J Exp Med 2007;204:2935-2948.
[31]Sobin LH, Wittekind C (eds):TNM Classification of Malignant Tumors (ed 6). New York, NY, Wiley-Liss,2002, pp 81-83
[32]Yamamoto J, Kosuge T, Saiura A, et al. Effectiveness of hepatic resection for early-stage hepatocellular carcinoma in cirrhotic patients:Subgroup analysis according to Milan criteria. Jpn J Clin Oncol 2007;37:287-295.
[33]Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-699.
[34]Vauthey JN, Lauwers GY, Esnaola NF, et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol 2002;20:1527-36.
[1]Wharton KA, Johansen KM, Artavanis-Tsakonas S. et al Nucleotide sequence from the neurogenic locus notch implies a gene product that shares homology with proteins containing EGF-like repeats. Cell 1985;43:567-581.
[2]Blaumueller CM, Qi H, Artavanis-Tsakonas S. et al Intracellular cleavage of Notch leads to a heterodimeric receptor on the plasma membrane. Cell 1997;90:281-291.
[3]Matthew D. Rand, Calcium depletion dissociates and activates heterodimeric Notch receptors. Mol Cell Biol, Mar.2000; 1825-1835.
[4]Mumm JS, Kopan R. Notch signaling:from the outside in. Dev Biol.2000;228:151-165.
[5]Edbauer D, Winkler E, Haass C. et al Reconstitution of gamma—secretase activity. Nat Cell Biol.2003;5:486-488.
[6]Iso T, Kedes L, Hamamori Y. HES and HERP families:multiple effectors of the Notch signaling pathway. J Cell Physiol.2003;194:237-255.
[7]Martinex Arias A,Zecchini V.Brennan K, CSL-independent Notch signalling:a checkpoint in cell fate decisions during development? Curr Opin Genet Dev 2002,12:524-533
[8]S Fre, M Huyghe, P Mourikis S Artavanis-Tsakonas et al Notch signals control the fate of immature progenitor cells in the intestine. Nature 2005; 435(7044):964-8
[9]JH van Es, ME van Gijn, H Clevers et al Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 2005; 435(7044): 959-63.
[101 Ellisen LW, Bird J, West DC et al TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 1991;66:649-661.
[11]AAndroutsellis-Theotokis, RR Leker, RD McKay et al Notch signaling regulates stem cell numbers in vitro and in vivo. Nature 2006; 442(7104):823-6.
[12]Nicolas M., Wolfer, Radtke F. et al Notchl functions as a tumor suppressor in mouse skin. Nat Genet.2003;33:416-421.
[13]Vauclair S., Nicolas, M., Radtke, F. et al Notchl is essential for postnatal hair follicle development and homeostasis. Dev. Biol.2005;284:184-193.
[14]Yamamoto N., Tanigaki K., and Honjo T. et al Notch/RBP-J signaling regulates epidermis/hair fate determination of hair follicular stem cells. Curr. Biol.2003; 13:333-338.
[15]Pan Y., Lin M.H. and Kopan R. et al gamma-secretase functions through Notch signaling to maintain skin appendages but is not required for their patterning or initial morphogenesis. Dev. Cell 2004;7:731-743.
[16]Devgan V., Mammucari C., Dotto G.P. et al p21WAF1/Cipl is a negative transcriptional regulator of Wnt4 expression downstream of Notchl activation. Genes Dev.2005;19:1485-1495.
[17]Karine Lefort, Anna Mandinova, G. Paolo Dotto et al Notchl is a p53 target gene involved in human keratinocyte tumor suppression through negative regulation of ROCK1/2 and MRCK(?) kinases Genes & Dev.2007; 21:562-577.
[18]Monzani E, Facchetti F, La Porta CA et al Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer.2007;43(5):935-46
[19]Croquelois A, Blindenbacher A, Terracciano L et al Inducible inactivation of Notchl causes nodular regenerative hyperplasia in mice. Hepatology 2005;41:487-496.
[20]Runzi Qi, Xuetao Cao et al Notchl signaling inhibits growth of human hepatocellular crcinoma through induction of cell cycle arrest and apoptosis. Cancer Res 2003; 63:8323-8329.
[21]M. Chiara Cantarini, Jack R. Wands et al Aspartyl-Asparagyl hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and Notch signaling mechanisms. Hepatology 2006;44:446-457.
[22]J Gao, C Chen, D Fan et al Expression of Jagged1 and its association with hepatitis B virus X protein in hepatocellular carcinoma. Biochem Biophys Res Commun 2007; 356(2):341-7.
[23]Jian Huang, Xin Zhang, Ze-Guang Han et al Up-regulation of DLK1 as an imprinted gene could contribute to human hepatocellular carcinoma.Carcinogenesis 2007; 28:1094-1103.
[24]Purow BW, Haque RM, Noel MW, et al. Expression of Notchl and its ligands, Delta— likel and Jaggedl, is critical for glioma cell survival and proliferation. Cancer Res.2005; 65 (6):2353-2363.
[25]Okano H, Imai T, Okabe M et al Musashi:a translational regulator of cell fate. J Cell Sci. 2002;115:1355-1359.
[26]Xing Fan, Irina Mikolaenko, G. Eberhart et al Notchl and Notch2 have opposite effects on embryonal brain tumor growth. Cancer Res 2004;64:7787-7793.
[27]Imatani A, Callahan R. et al Identification of a novel NOTCH-4/INT-3 RNA species encoding an activated gene product in certain human tumor cell lines. Oncogene 2000;19:223-231.
[28]Weij S, Rizzo P, Braid M, et al. Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med.2002;8:979-986.
[29]Parr C, Watkins G, Jiang WG. et al The possible correlation of Notch-1 and Notch-2 with clinical outcome and tumour clinicopathological parameters in human breast cancer. Int J Mol Med.2004;14:779-786.
[30]Dickson BC, Mulligan AM, Reedijk M et al High-level JAG1 mRNA and protein predict poor outcome in breast cancer. Mod Pathol.2007;20(6):685-93.
[31]S Liu, G Dontu, and MS Wicha Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Res 2005; 7(3):86-95.
[32]Curry CL, Reed LL, Foreman KE. et al Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells. Oncogene.2005;24:6333-6344.
[33]Anna Bigas, David I. K. Martin,and Laurie A. Milner Notchl and Notch2 Inhibit Myeloid Differentiation in Response to Different Cytokines Mol Cell Biol,1998;18:2324-2333.
[34]Guan E, Wang J, Hoffman T. et al T cell leukemia-associated human Notch/translocation-associated Notch homologue has I kappa B-like activity and physically interacts with nuclear factor-kappa B proteins in T cells. J Exp Med.1996;183:2025-2032.